Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Disaster Planning | 5 | 2018 | 559 | 1.210 |
Why?
|
Quality of Life | 37 | 2018 | 13510 | 0.810 |
Why?
|
Information Dissemination | 2 | 2021 | 1141 | 0.750 |
Why?
|
Hypoglycemic Agents | 9 | 2024 | 3110 | 0.710 |
Why?
|
Civil Defense | 3 | 2018 | 115 | 0.690 |
Why?
|
Public Health Administration | 3 | 2018 | 242 | 0.650 |
Why?
|
Hospitalization | 8 | 2019 | 10847 | 0.640 |
Why?
|
Demyelinating Diseases | 1 | 2019 | 358 | 0.540 |
Why?
|
Vaccines | 2 | 2022 | 843 | 0.530 |
Why?
|
Medication Reconciliation | 1 | 2018 | 153 | 0.530 |
Why?
|
Child, Hospitalized | 1 | 2017 | 182 | 0.510 |
Why?
|
Jaundice, Neonatal | 2 | 2004 | 70 | 0.460 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2016 | 232 | 0.460 |
Why?
|
Arthritis, Infectious | 1 | 2017 | 348 | 0.450 |
Why?
|
Osteomyelitis | 1 | 2017 | 408 | 0.430 |
Why?
|
Psychometrics | 6 | 2018 | 3066 | 0.410 |
Why?
|
Insulin, Long-Acting | 1 | 2012 | 59 | 0.400 |
Why?
|
Anaphylaxis | 1 | 2019 | 758 | 0.400 |
Why?
|
Legislation, Medical | 1 | 2012 | 99 | 0.400 |
Why?
|
Public Health Practice | 1 | 2014 | 221 | 0.390 |
Why?
|
Emergencies | 1 | 2018 | 1221 | 0.380 |
Why?
|
Food Hypersensitivity | 1 | 2019 | 734 | 0.380 |
Why?
|
Models, Theoretical | 4 | 2014 | 3580 | 0.360 |
Why?
|
Bacteremia | 1 | 2017 | 985 | 0.360 |
Why?
|
Ambulatory Care | 3 | 2018 | 2784 | 0.350 |
Why?
|
Nifedipine | 3 | 1998 | 220 | 0.340 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 1014 | 0.330 |
Why?
|
Hypolipidemic Agents | 3 | 2003 | 609 | 0.330 |
Why?
|
Benchmarking | 3 | 2004 | 1059 | 0.320 |
Why?
|
Public Health | 2 | 2021 | 2680 | 0.320 |
Why?
|
Glipizide | 2 | 1998 | 48 | 0.310 |
Why?
|
Patient Compliance | 7 | 2013 | 2701 | 0.310 |
Why?
|
Sarcoma, Kaposi | 5 | 2002 | 375 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2024 | 12253 | 0.300 |
Why?
|
Blood Glucose | 10 | 2024 | 6435 | 0.300 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2012 | 3447 | 0.290 |
Why?
|
Stress, Psychological | 5 | 2012 | 4530 | 0.280 |
Why?
|
Hypertension | 15 | 2013 | 8617 | 0.270 |
Why?
|
Health Services Research | 4 | 2000 | 1818 | 0.270 |
Why?
|
United States | 23 | 2021 | 73186 | 0.260 |
Why?
|
Adamantane | 2 | 2024 | 148 | 0.260 |
Why?
|
Antihypertensive Agents | 9 | 2013 | 2027 | 0.260 |
Why?
|
Hypoglycemia | 4 | 2024 | 895 | 0.250 |
Why?
|
Dipeptides | 2 | 2024 | 386 | 0.240 |
Why?
|
Diabetes Mellitus | 4 | 2019 | 5892 | 0.240 |
Why?
|
Phototherapy | 2 | 2004 | 368 | 0.230 |
Why?
|
Cross-Sectional Studies | 13 | 2021 | 26395 | 0.230 |
Why?
|
HIV Infections | 12 | 2014 | 17591 | 0.220 |
Why?
|
Male | 77 | 2024 | 365203 | 0.220 |
Why?
|
Hyperbilirubinemia | 1 | 2003 | 74 | 0.220 |
Why?
|
Adolescent | 27 | 2020 | 89244 | 0.220 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2005 | 2203 | 0.220 |
Why?
|
Child, Preschool | 11 | 2019 | 42683 | 0.220 |
Why?
|
Humans | 122 | 2024 | 768970 | 0.220 |
Why?
|
Blood Glucose Self-Monitoring | 2 | 2024 | 475 | 0.210 |
Why?
|
Hematologic Neoplasms | 3 | 2023 | 1907 | 0.210 |
Why?
|
Infant, Newborn | 12 | 2019 | 26428 | 0.210 |
Why?
|
Hyperlipidemias | 3 | 2003 | 773 | 0.210 |
Why?
|
Patient Satisfaction | 4 | 2013 | 3492 | 0.210 |
Why?
|
Glucosides | 2 | 2024 | 533 | 0.200 |
Why?
|
Insulin | 5 | 2015 | 6610 | 0.200 |
Why?
|
Athletic Injuries | 1 | 2012 | 1245 | 0.200 |
Why?
|
Didanosine | 1 | 2002 | 151 | 0.200 |
Why?
|
Female | 67 | 2024 | 397515 | 0.200 |
Why?
|
Atenolol | 2 | 1993 | 99 | 0.190 |
Why?
|
Patient Acceptance of Health Care | 3 | 2021 | 3235 | 0.190 |
Why?
|
Zidovudine | 2 | 1994 | 625 | 0.180 |
Why?
|
Asthma | 2 | 2019 | 6293 | 0.180 |
Why?
|
Hate | 1 | 2020 | 10 | 0.180 |
Why?
|
Communications Media | 1 | 2021 | 42 | 0.180 |
Why?
|
Amlodipine | 2 | 2013 | 84 | 0.180 |
Why?
|
Brain Concussion | 1 | 2012 | 1436 | 0.180 |
Why?
|
Caregivers | 2 | 2023 | 2308 | 0.180 |
Why?
|
Risk Assessment | 5 | 2017 | 24333 | 0.180 |
Why?
|
Drug Therapy, Combination | 6 | 2024 | 6320 | 0.170 |
Why?
|
Benzhydryl Compounds | 2 | 2024 | 944 | 0.170 |
Why?
|
Sex Distribution | 2 | 2017 | 2280 | 0.170 |
Why?
|
CD4 Lymphocyte Count | 5 | 2012 | 2598 | 0.170 |
Why?
|
Onychomycosis | 1 | 2000 | 50 | 0.170 |
Why?
|
Child | 14 | 2019 | 80960 | 0.160 |
Why?
|
Age Distribution | 2 | 2017 | 2875 | 0.160 |
Why?
|
Adult | 56 | 2024 | 223851 | 0.160 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2018 | 365 | 0.160 |
Why?
|
Captopril | 4 | 1993 | 262 | 0.150 |
Why?
|
Cyclohexanols | 1 | 1999 | 126 | 0.150 |
Why?
|
HIV Wasting Syndrome | 1 | 1999 | 99 | 0.150 |
Why?
|
Double-Blind Method | 16 | 2020 | 12467 | 0.150 |
Why?
|
Infant | 7 | 2019 | 36556 | 0.150 |
Why?
|
Young Adult | 13 | 2020 | 60131 | 0.150 |
Why?
|
Interferon-alpha | 1 | 2002 | 910 | 0.140 |
Why?
|
Diabetes Complications | 3 | 2019 | 1320 | 0.140 |
Why?
|
Aged | 44 | 2024 | 171786 | 0.140 |
Why?
|
Telephone | 2 | 2013 | 630 | 0.140 |
Why?
|
Efficiency | 1 | 2000 | 480 | 0.140 |
Why?
|
Middle Aged | 51 | 2024 | 223737 | 0.140 |
Why?
|
Communication | 2 | 2021 | 3908 | 0.140 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2018 | 193 | 0.140 |
Why?
|
Anti-HIV Agents | 4 | 2013 | 4576 | 0.140 |
Why?
|
Geriatric Assessment | 2 | 2022 | 1422 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2021 | 4056 | 0.140 |
Why?
|
Respiration, Artificial | 2 | 2019 | 2725 | 0.130 |
Why?
|
Socioeconomic Factors | 4 | 2016 | 7861 | 0.130 |
Why?
|
Crime Victims | 1 | 2020 | 347 | 0.130 |
Why?
|
Breast Feeding | 1 | 2004 | 1364 | 0.130 |
Why?
|
Proctocolectomy, Restorative | 1 | 2018 | 191 | 0.130 |
Why?
|
Risk Factors | 10 | 2019 | 74976 | 0.120 |
Why?
|
Insulin Infusion Systems | 3 | 1985 | 221 | 0.120 |
Why?
|
Calcium Channel Blockers | 1 | 1998 | 691 | 0.120 |
Why?
|
Glucagon-Like Peptides | 1 | 2016 | 157 | 0.120 |
Why?
|
Erectile Dysfunction | 1 | 2018 | 445 | 0.110 |
Why?
|
Sulfonylurea Compounds | 2 | 2020 | 220 | 0.110 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 287 | 0.110 |
Why?
|
Primary Health Care | 4 | 2019 | 4748 | 0.110 |
Why?
|
Diabetic Retinopathy | 4 | 1988 | 1299 | 0.110 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 234 | 0.110 |
Why?
|
Obesity | 1 | 2016 | 13091 | 0.110 |
Why?
|
Databases, Factual | 3 | 2019 | 8094 | 0.110 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 1993 | 28 | 0.110 |
Why?
|
Epidemics | 1 | 2019 | 517 | 0.110 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2018 | 2442 | 0.110 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2013 | 60 | 0.110 |
Why?
|
Psychiatric Status Rating Scales | 4 | 2018 | 6030 | 0.110 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2013 | 104 | 0.100 |
Why?
|
Musculoskeletal Diseases | 1 | 2019 | 599 | 0.100 |
Why?
|
Syndrome | 1 | 2019 | 3274 | 0.100 |
Why?
|
Immunoglobulin A | 1 | 2016 | 992 | 0.100 |
Why?
|
Practice Guidelines as Topic | 3 | 2004 | 7460 | 0.100 |
Why?
|
Louisiana | 1 | 2012 | 104 | 0.100 |
Why?
|
Vasculitis | 2 | 2016 | 525 | 0.100 |
Why?
|
Renal Artery Obstruction | 1 | 2013 | 217 | 0.100 |
Why?
|
History, 21st Century | 1 | 2018 | 1575 | 0.100 |
Why?
|
Vaccination | 2 | 2022 | 3438 | 0.100 |
Why?
|
Metformin | 1 | 2020 | 909 | 0.100 |
Why?
|
Barbering | 1 | 2011 | 12 | 0.100 |
Why?
|
Economics, Pharmaceutical | 1 | 1992 | 88 | 0.100 |
Why?
|
Absenteeism | 2 | 1998 | 247 | 0.100 |
Why?
|
Random Allocation | 9 | 2017 | 2394 | 0.100 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 539 | 0.100 |
Why?
|
Injections, Subcutaneous | 4 | 2007 | 687 | 0.100 |
Why?
|
Interpersonal Relations | 1 | 1999 | 1437 | 0.090 |
Why?
|
Counseling | 1 | 2019 | 1554 | 0.090 |
Why?
|
Urinary Incontinence | 1 | 1996 | 496 | 0.090 |
Why?
|
Retrospective Studies | 13 | 2019 | 81903 | 0.090 |
Why?
|
Auditory Fatigue | 1 | 2010 | 9 | 0.090 |
Why?
|
Enalapril | 1 | 1993 | 317 | 0.090 |
Why?
|
Reproducibility of Results | 10 | 2018 | 20245 | 0.090 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 428 | 0.090 |
Why?
|
Treatment Outcome | 13 | 2024 | 65480 | 0.090 |
Why?
|
Occupational Diseases | 1 | 2019 | 1458 | 0.090 |
Why?
|
Factor Analysis, Statistical | 2 | 2012 | 1002 | 0.090 |
Why?
|
Work Capacity Evaluation | 2 | 2006 | 42 | 0.090 |
Why?
|
Health Status | 4 | 2004 | 4095 | 0.090 |
Why?
|
Hospital Costs | 1 | 2016 | 959 | 0.090 |
Why?
|
Health Status Indicators | 3 | 2001 | 971 | 0.090 |
Why?
|
State Government | 1 | 2012 | 389 | 0.080 |
Why?
|
Hearing Loss, Noise-Induced | 1 | 2010 | 144 | 0.080 |
Why?
|
Logistic Models | 3 | 2017 | 13318 | 0.080 |
Why?
|
Technology, High-Cost | 1 | 1988 | 32 | 0.080 |
Why?
|
Attitude to Health | 3 | 2004 | 2025 | 0.080 |
Why?
|
Intubation, Intratracheal | 1 | 2017 | 1359 | 0.080 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15951 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2014 | 718 | 0.080 |
Why?
|
Adrenal Cortex Hormones | 2 | 2008 | 1892 | 0.080 |
Why?
|
Lymphoma, AIDS-Related | 2 | 1999 | 79 | 0.080 |
Why?
|
Cost of Illness | 1 | 1998 | 1960 | 0.080 |
Why?
|
Noise | 1 | 2010 | 295 | 0.080 |
Why?
|
Internet | 1 | 2020 | 3112 | 0.080 |
Why?
|
Clinical Trials as Topic | 11 | 1999 | 8055 | 0.080 |
Why?
|
Technology, Radiologic | 1 | 1988 | 160 | 0.080 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2012 | 453 | 0.080 |
Why?
|
Antirheumatic Agents | 2 | 2008 | 1381 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3744 | 0.070 |
Why?
|
Taste | 2 | 1986 | 190 | 0.070 |
Why?
|
General Surgery | 1 | 2019 | 1722 | 0.070 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2010 | 374 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2007 | 4862 | 0.070 |
Why?
|
Acute Disease | 1 | 2017 | 7245 | 0.070 |
Why?
|
Incidence | 5 | 2019 | 21547 | 0.070 |
Why?
|
Government Agencies | 1 | 2007 | 161 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2422 | 0.070 |
Why?
|
Football | 1 | 2012 | 506 | 0.070 |
Why?
|
Emergency Medical Services | 1 | 2018 | 1947 | 0.070 |
Why?
|
Depression | 2 | 2018 | 8231 | 0.070 |
Why?
|
Inservice Training | 1 | 2009 | 375 | 0.070 |
Why?
|
Self-Assessment | 2 | 1998 | 400 | 0.070 |
Why?
|
Hyperbilirubinemia, Neonatal | 1 | 2006 | 30 | 0.070 |
Why?
|
Depressive Disorder | 1 | 1999 | 3723 | 0.070 |
Why?
|
Causality | 1 | 2012 | 1256 | 0.060 |
Why?
|
Carcinoma, Basal Cell | 1 | 2011 | 565 | 0.060 |
Why?
|
Health Care Costs | 1 | 2019 | 3270 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2012 | 2108 | 0.060 |
Why?
|
Patient Preference | 1 | 2013 | 947 | 0.060 |
Why?
|
Achievement | 1 | 2007 | 288 | 0.060 |
Why?
|
Length of Stay | 2 | 2016 | 6526 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2002 | 11886 | 0.060 |
Why?
|
Follow-Up Studies | 8 | 2018 | 39394 | 0.060 |
Why?
|
Herpes Zoster | 1 | 2007 | 252 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2005 | 1795 | 0.060 |
Why?
|
Cognition | 2 | 2021 | 7081 | 0.060 |
Why?
|
Viral Load | 2 | 2012 | 3398 | 0.060 |
Why?
|
Task Performance and Analysis | 1 | 2009 | 771 | 0.060 |
Why?
|
Prognosis | 5 | 2018 | 30046 | 0.060 |
Why?
|
Streptococcus mutans | 1 | 1984 | 99 | 0.060 |
Why?
|
Nutritional Status | 1 | 1993 | 1627 | 0.060 |
Why?
|
Occupations | 1 | 2007 | 516 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 892 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2188 | 0.060 |
Why?
|
Data Collection | 4 | 2016 | 3324 | 0.060 |
Why?
|
Research Support as Topic | 1 | 1988 | 696 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9684 | 0.060 |
Why?
|
Sexual Behavior | 4 | 2018 | 2200 | 0.060 |
Why?
|
Self Efficacy | 2 | 2007 | 643 | 0.060 |
Why?
|
Administration, Inhalation | 1 | 2007 | 1169 | 0.060 |
Why?
|
Medical Illustration | 1 | 2004 | 135 | 0.050 |
Why?
|
Regression Analysis | 4 | 2018 | 6346 | 0.050 |
Why?
|
Enterobacteriaceae | 1 | 1985 | 161 | 0.050 |
Why?
|
Nurses | 1 | 2013 | 2501 | 0.050 |
Why?
|
Survival Analysis | 6 | 2002 | 10115 | 0.050 |
Why?
|
Evaluation Studies as Topic | 2 | 2009 | 1629 | 0.050 |
Why?
|
Commerce | 1 | 1988 | 613 | 0.050 |
Why?
|
Information Systems | 1 | 1985 | 400 | 0.050 |
Why?
|
Hospital Mortality | 1 | 2017 | 5369 | 0.050 |
Why?
|
Hybrid Cells | 1 | 1983 | 421 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10592 | 0.050 |
Why?
|
Fluorescein Angiography | 2 | 1985 | 1086 | 0.050 |
Why?
|
Computers | 1 | 1985 | 592 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 1988 | 806 | 0.050 |
Why?
|
Culture Media | 1 | 1984 | 898 | 0.050 |
Why?
|
Poisson Distribution | 1 | 2003 | 508 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 2 | 2008 | 3780 | 0.050 |
Why?
|
Erythropoietin | 1 | 2006 | 718 | 0.050 |
Why?
|
Coronary Disease | 3 | 2003 | 5919 | 0.050 |
Why?
|
Bilirubin | 1 | 2003 | 438 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3200 | 0.050 |
Why?
|
Body Weight | 1 | 2012 | 4628 | 0.050 |
Why?
|
Pediatrics | 1 | 2016 | 3628 | 0.050 |
Why?
|
Population Surveillance | 1 | 2012 | 2597 | 0.050 |
Why?
|
Mallory-Weiss Syndrome | 1 | 1981 | 2 | 0.050 |
Why?
|
Emergency Service, Hospital | 2 | 2018 | 7957 | 0.050 |
Why?
|
Insulin Resistance | 1 | 2015 | 3982 | 0.050 |
Why?
|
HIV | 2 | 2005 | 1597 | 0.050 |
Why?
|
Etoposide | 1 | 2002 | 639 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 1999 | 1376 | 0.050 |
Why?
|
Influenza, Human | 1 | 2012 | 1542 | 0.050 |
Why?
|
Meiosis | 1 | 1983 | 327 | 0.040 |
Why?
|
Computer Simulation | 1 | 2014 | 6291 | 0.040 |
Why?
|
Aged, 80 and over | 7 | 2018 | 59739 | 0.040 |
Why?
|
Urination Disorders | 1 | 2002 | 238 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2003 | 12095 | 0.040 |
Why?
|
Inpatients | 1 | 2012 | 2569 | 0.040 |
Why?
|
Technology | 1 | 2023 | 296 | 0.040 |
Why?
|
Albuminuria | 1 | 1984 | 658 | 0.040 |
Why?
|
Eating | 1 | 2007 | 1542 | 0.040 |
Why?
|
Peripheral Vascular Diseases | 1 | 2003 | 489 | 0.040 |
Why?
|
Qualitative Research | 1 | 2011 | 3143 | 0.040 |
Why?
|
Treatment Refusal | 1 | 2003 | 433 | 0.040 |
Why?
|
Cohort Studies | 6 | 2011 | 41808 | 0.040 |
Why?
|
Toilet Facilities | 1 | 2019 | 26 | 0.040 |
Why?
|
Body Mass Index | 1 | 2017 | 13055 | 0.040 |
Why?
|
Zinc | 1 | 1983 | 677 | 0.040 |
Why?
|
Fecal Incontinence | 1 | 2002 | 246 | 0.040 |
Why?
|
Neutropenia | 2 | 2002 | 893 | 0.040 |
Why?
|
Time Factors | 10 | 2019 | 40261 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2003 | 1056 | 0.040 |
Why?
|
Quality Assurance, Health Care | 2 | 1999 | 2182 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1903 | 0.040 |
Why?
|
Calibration | 2 | 1998 | 822 | 0.040 |
Why?
|
Cross Infection | 1 | 2008 | 1425 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2002 | 1157 | 0.040 |
Why?
|
Program Evaluation | 1 | 2007 | 2508 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 622 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2003 | 3253 | 0.040 |
Why?
|
Delayed-Action Preparations | 2 | 1993 | 969 | 0.040 |
Why?
|
Methyldopa | 2 | 1987 | 18 | 0.040 |
Why?
|
Infant, Premature | 2 | 2004 | 2123 | 0.040 |
Why?
|
Spain | 1 | 1998 | 485 | 0.040 |
Why?
|
Pseudomonas aeruginosa | 1 | 1985 | 1276 | 0.030 |
Why?
|
Anemia | 1 | 2006 | 1517 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2008 | 10765 | 0.030 |
Why?
|
Birth Weight | 2 | 2004 | 2121 | 0.030 |
Why?
|
Heart Arrest | 1 | 2006 | 1515 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 1987 | 2666 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2002 | 967 | 0.030 |
Why?
|
Gastric Juice | 1 | 1976 | 59 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2003 | 1076 | 0.030 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 1999 | 491 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 4064 | 0.030 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15661 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1999 | 664 | 0.030 |
Why?
|
Administration, Oral | 3 | 2005 | 4040 | 0.030 |
Why?
|
Propranolol | 2 | 1987 | 493 | 0.030 |
Why?
|
Habituation, Psychophysiologic | 1 | 1976 | 147 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 1997 | 14752 | 0.030 |
Why?
|
Multiple Sclerosis | 3 | 1986 | 3250 | 0.030 |
Why?
|
Drug Delivery Systems | 2 | 1998 | 2238 | 0.030 |
Why?
|
Placebos | 1 | 1999 | 1667 | 0.030 |
Why?
|
Nadolol | 1 | 1994 | 29 | 0.030 |
Why?
|
Software | 2 | 1986 | 4479 | 0.030 |
Why?
|
Diuretics | 2 | 1987 | 614 | 0.030 |
Why?
|
Employment | 1 | 2000 | 1114 | 0.030 |
Why?
|
Neoplasms | 1 | 2023 | 22389 | 0.030 |
Why?
|
Patients | 1 | 2000 | 908 | 0.030 |
Why?
|
Critical Care | 1 | 2006 | 2716 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2000 | 5544 | 0.030 |
Why?
|
Models, Biological | 3 | 2017 | 9499 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 14201 | 0.030 |
Why?
|
Homosexuality | 1 | 2014 | 269 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1981 | 1126 | 0.030 |
Why?
|
Bone Density | 2 | 1997 | 3574 | 0.030 |
Why?
|
Decision Making, Organizational | 1 | 1994 | 136 | 0.030 |
Why?
|
Data Interpretation, Statistical | 2 | 1994 | 2714 | 0.030 |
Why?
|
Massachusetts | 2 | 2020 | 8894 | 0.030 |
Why?
|
Melanoma | 1 | 2011 | 5709 | 0.030 |
Why?
|
Self Concept | 1 | 1999 | 1046 | 0.030 |
Why?
|
Haiti | 1 | 2014 | 553 | 0.030 |
Why?
|
Focus Groups | 1 | 1999 | 1462 | 0.030 |
Why?
|
Value of Life | 1 | 1992 | 98 | 0.020 |
Why?
|
Social Behavior | 1 | 1999 | 1146 | 0.020 |
Why?
|
Renal Artery | 1 | 2013 | 353 | 0.020 |
Why?
|
Uremia | 1 | 1993 | 202 | 0.020 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1995 | 399 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2011 | 5864 | 0.020 |
Why?
|
Models, Econometric | 1 | 1992 | 215 | 0.020 |
Why?
|
Heptanoic Acids | 1 | 2013 | 344 | 0.020 |
Why?
|
Research Design | 2 | 2000 | 6214 | 0.020 |
Why?
|
Terminology as Topic | 1 | 1999 | 1541 | 0.020 |
Why?
|
Specialization | 1 | 1996 | 780 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2350 | 0.020 |
Why?
|
Physical Exertion | 1 | 1994 | 668 | 0.020 |
Why?
|
Patient Selection | 1 | 2003 | 4265 | 0.020 |
Why?
|
Texas | 1 | 2011 | 410 | 0.020 |
Why?
|
Models, Organizational | 1 | 1994 | 549 | 0.020 |
Why?
|
Carcinoma | 1 | 2002 | 2340 | 0.020 |
Why?
|
Animals | 4 | 2019 | 169335 | 0.020 |
Why?
|
Affective Symptoms | 1 | 1993 | 418 | 0.020 |
Why?
|
Biopsy | 1 | 2002 | 6805 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1994 | 1609 | 0.020 |
Why?
|
Hydrochlorothiazide | 2 | 1987 | 95 | 0.020 |
Why?
|
HIV-1 | 1 | 2007 | 6962 | 0.020 |
Why?
|
Mental Health | 2 | 1999 | 3275 | 0.020 |
Why?
|
Fatigue | 2 | 2006 | 1557 | 0.020 |
Why?
|
Angioplasty, Balloon | 1 | 2013 | 592 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 1999 | 2434 | 0.020 |
Why?
|
Life Style | 2 | 2019 | 3931 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 1995 | 1758 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2002 | 11230 | 0.020 |
Why?
|
Women's Health | 1 | 2018 | 2081 | 0.020 |
Why?
|
Maine | 1 | 2009 | 146 | 0.020 |
Why?
|
Policy Making | 1 | 1992 | 546 | 0.020 |
Why?
|
Insulin-Secreting Cells | 1 | 2015 | 899 | 0.020 |
Why?
|
Osteoporosis | 1 | 1997 | 1606 | 0.020 |
Why?
|
Forecasting | 1 | 2017 | 2945 | 0.020 |
Why?
|
Vaginitis | 1 | 1988 | 50 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1980 | 2543 | 0.020 |
Why?
|
Medicine | 1 | 1996 | 947 | 0.020 |
Why?
|
Nurse-Patient Relations | 1 | 2008 | 101 | 0.020 |
Why?
|
Prostatitis | 1 | 1988 | 102 | 0.020 |
Why?
|
Pyrroles | 1 | 2013 | 1125 | 0.020 |
Why?
|
Drug Combinations | 1 | 2013 | 2089 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2664 | 0.020 |
Why?
|
Bleomycin | 2 | 1998 | 493 | 0.020 |
Why?
|
Epoetin Alfa | 1 | 2006 | 78 | 0.020 |
Why?
|
Decision Support Techniques | 2 | 1997 | 2008 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1389 | 0.020 |
Why?
|
Blood Pressure | 4 | 1993 | 8544 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2013 | 972 | 0.020 |
Why?
|
Prevalence | 2 | 2010 | 15879 | 0.020 |
Why?
|
Saquinavir | 1 | 2005 | 29 | 0.020 |
Why?
|
Risk | 3 | 2008 | 9621 | 0.020 |
Why?
|
Age Factors | 4 | 2006 | 18435 | 0.020 |
Why?
|
Statistics as Topic | 1 | 1992 | 2360 | 0.020 |
Why?
|
RNA, Viral | 2 | 2005 | 2871 | 0.020 |
Why?
|
Classification | 1 | 1986 | 128 | 0.020 |
Why?
|
Prospective Studies | 5 | 2018 | 54962 | 0.020 |
Why?
|
Stress, Physiological | 1 | 1993 | 1408 | 0.020 |
Why?
|
Vincristine | 2 | 1998 | 1040 | 0.020 |
Why?
|
Fractures, Bone | 1 | 1997 | 2063 | 0.020 |
Why?
|
Capsules | 1 | 2005 | 193 | 0.020 |
Why?
|
Coronary Vessels | 1 | 2016 | 3124 | 0.020 |
Why?
|
Individuality | 1 | 1987 | 307 | 0.020 |
Why?
|
Bacitracin | 1 | 1984 | 24 | 0.020 |
Why?
|
Tellurium | 1 | 1984 | 23 | 0.010 |
Why?
|
Agar | 1 | 1984 | 51 | 0.010 |
Why?
|
Boston | 1 | 2018 | 9377 | 0.010 |
Why?
|
Retinal Artery | 1 | 1985 | 109 | 0.010 |
Why?
|
Sucrose | 1 | 1984 | 157 | 0.010 |
Why?
|
alpha-Macroglobulins | 1 | 1983 | 60 | 0.010 |
Why?
|
Central Nervous System | 1 | 1991 | 1346 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2006 | 13698 | 0.010 |
Why?
|
Body Composition | 1 | 1993 | 2462 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3491 | 0.010 |
Why?
|
Work Schedule Tolerance | 1 | 1987 | 553 | 0.010 |
Why?
|
Myocardial Ischemia | 1 | 1994 | 2139 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3838 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6547 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1985 | 945 | 0.010 |
Why?
|
HIV Core Protein p24 | 1 | 2002 | 247 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 1994 | 2593 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8749 | 0.010 |
Why?
|
Aneurysm | 1 | 1985 | 343 | 0.010 |
Why?
|
Cyclophosphamide | 2 | 1998 | 2227 | 0.010 |
Why?
|
Lupus Erythematosus, Systemic | 2 | 1985 | 2171 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9384 | 0.010 |
Why?
|
Rheumatology | 2 | 1985 | 617 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2003 | 11521 | 0.010 |
Why?
|
Medication Adherence | 1 | 2013 | 2192 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8559 | 0.010 |
Why?
|
Tooth | 1 | 1983 | 210 | 0.010 |
Why?
|
Health Surveys | 1 | 2011 | 4055 | 0.010 |
Why?
|
Urinary Tract Infections | 1 | 1988 | 805 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1994 | 4413 | 0.010 |
Why?
|
Methotrexate | 2 | 1998 | 1723 | 0.010 |
Why?
|
Hematemesis | 1 | 1981 | 22 | 0.010 |
Why?
|
Doxorubicin | 2 | 1998 | 2234 | 0.010 |
Why?
|
Asphyxia Neonatorum | 1 | 1982 | 111 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2007 | 1794 | 0.010 |
Why?
|
Karyotyping | 1 | 1983 | 1177 | 0.010 |
Why?
|
Stroke | 1 | 2003 | 9756 | 0.010 |
Why?
|
Hemoglobins | 1 | 2006 | 1531 | 0.010 |
Why?
|
Dexamethasone | 2 | 1998 | 1965 | 0.010 |
Why?
|
Serum Albumin | 1 | 1983 | 677 | 0.010 |
Why?
|
Self Care | 1 | 2005 | 801 | 0.010 |
Why?
|
Weight Gain | 1 | 2010 | 2359 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2008 | 22296 | 0.010 |
Why?
|
Foscarnet | 1 | 1999 | 36 | 0.010 |
Why?
|
Sigmoid Neoplasms | 1 | 1980 | 53 | 0.010 |
Why?
|
Indinavir | 1 | 1999 | 73 | 0.010 |
Why?
|
Creatinine | 1 | 1985 | 1917 | 0.010 |
Why?
|
Lens, Crystalline | 1 | 1982 | 387 | 0.010 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2006 | 1027 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2013 | 2297 | 0.010 |
Why?
|
Cytomegalovirus Retinitis | 1 | 1999 | 56 | 0.010 |
Why?
|
Connecticut | 1 | 1980 | 365 | 0.010 |
Why?
|
Leadership | 1 | 2009 | 1396 | 0.010 |
Why?
|
Periodontal Diseases | 1 | 1983 | 455 | 0.010 |
Why?
|
Gastroscopy | 1 | 1981 | 213 | 0.010 |
Why?
|
|